证券代码：002144 股票简称：宏达高科 公告编号：2024-021 1、以 3 票同意、0 票反对、0 票弃权的表决结果审议通过了《关于选举第八 届监事会主席的议案》。 与会监事经认真审议，一致同意选举陆维敏先生（简历详见附件）为公司第 八届监事会主席，任期与第八届监事会一致，即自 2024 年 5 月 28 日至 2027 年 5 月 27 日。 备查文件：第八届监事会第一次会议决议。 宏达高科控股股份有限公司 第八届监事会第一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 宏达高科控股股份有限公司（以下简称"公司"）于 2024 年 5 月 28 日召开 了 2023 年年度股东大会，审议通过了《选举股东代表监事的议案》，选举了陆维 敏先生、许铨先生为公司监事，他们与 2024 年 5 月 15 日召开的 2024 年第一次 职工代表大会选举产生的职工代表监事周美玲女士一起组成了公司第八届监事 会。同日，在海宁市许村镇大桥路 275 号公司会议室召开了第八届监事会第一次 会议。 本次会议由监事陆维敏先生主持，应到监事 3 位，实到监事 ...

北京德恒律师事务所 关于宏达高科控股股份有限公司 二〇二三年年度股东大会的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 北京德恒律师事务所 关于宏达高科控股股份有限公司二〇二三年度股东大会的法律意见 北京德恒律师事务所 关于宏达高科控股股份有限公司 二〇二三年年度股东大会的 法律意见 编号：01G20240435 致：宏达高科控股股份有限公司 北京德恒律师事务所受宏达高科控股股份有限公司（下称"公司"或"宏达 高科"）委托，指派马恺律师、徐晓璇律师（下称"本所律师"）列席公司于 2024 年 5 月 28 日 14:00 召开的二〇二三年年度股东大会（下称"本次股东大会"）， 对本次股东大会进行见证，并出具法律意见。 本法律意见根据《中华人民共和国公司法》（下称"《公司法》"）、《中 华人民共和国证券法》（下称"《证券法》"）、《上市公司股东大会规则》（下 称"《股东大会规则》"）等有关法律、法规和规范性文件以及《宏达高科控股 股份有限公司章程》（下称"《公司章程》"）和《宏达高科控股股份有限公司 股东大 ...

Financial Performance - The company's revenue for Q1 2024 was CNY 120,997,467.59, representing a 0.70% increase compared to CNY 120,153,487.21 in the same period last year[5]. - Net profit attributable to shareholders was CNY 17,877,888.35, up 3.80% from CNY 17,223,917.74 year-on-year[5]. - The company's net profit for Q1 2024 was CNY 18,056,268.14, an increase from CNY 17,522,185.87 in Q1 2023, representing a growth of approximately 3.06%[18]. - Operating revenue for Q1 2024 was CNY 134,889,551.28, compared to CNY 131,195,516.79 in Q1 2023, indicating a year-over-year increase of about 2.06%[21]. - The total operating profit for Q1 2024 was CNY 20,554,810.76, compared to CNY 19,705,509.83 in Q1 2023, marking an increase of approximately 4.31%[18]. - The total comprehensive income for Q1 2024 was CNY 6,724,068.14, compared to CNY 19,325,035.87 in Q1 2023, indicating a significant decrease[19]. Cash Flow and Assets - The net cash flow from operating activities increased by 15.02% to CNY 19,135,862.21 from CNY 16,636,610.36 in the previous year[5]. - Cash and cash equivalents increased by 803.02% to CNY 123,239,403.06, primarily due to net increases from investment and financing activities[9]. - Cash and cash equivalents increased to RMB 657,844,131.12 from RMB 536,148,860.18, representing a growth of 22.67%[14]. - The cash and cash equivalents at the end of Q1 2024 amounted to CNY 657,803,156.18, an increase from CNY 512,266,644.24 at the end of Q1 2023, representing a growth of approximately 28.38%[22]. - Total assets as of March 31, 2024, were CNY 2,228,108,415.79, a 2.66% increase from CNY 2,170,375,592.53 at the end of the previous year[5]. - Total current assets rose to RMB 916,204,064.93, up 9.34% from RMB 838,089,609.64 at the beginning of the period[15]. - Total assets increased to RMB 2,228,108,415.79 from RMB 2,170,375,592.53, reflecting a growth of 2.65%[16]. Liabilities and Shareholder Information - Total liabilities increased to RMB 220,487,529.96 from RMB 169,478,774.84, an increase of 30.06%[16]. - The number of ordinary shareholders at the end of the reporting period was 17,473, with the largest shareholder holding 24.10% of the shares[10]. - The company's major shareholder, Mr. Shen Guofu, increased his stake by acquiring 1,305,700 shares, bringing his total ownership to 42,600,090 shares, or 24.10% of the total share capital[12]. - Short-term borrowings surged by 725.52% to CNY 83,590,847.81, attributed to new low-interest bank loans[9]. Expenses and Financial Costs - Total operating costs decreased to RMB 104,055,545.06, down 2.58% from RMB 106,830,552.14 in the previous year[17]. - The company experienced a 139.25% increase in financial expenses, mainly due to increased foreign exchange gains[9]. - The company's tax expenses for Q1 2024 were CNY 2,514,074.23, up from CNY 2,133,700.40 in Q1 2023, reflecting an increase of about 17.80%[18]. - The company reported a financial expense of CNY -2,320,733.43 in Q1 2024, compared to CNY -970,017.78 in Q1 2023, reflecting a worsening in financial costs[18]. Investments and R&D - The company holds a long-term equity investment of RMB 430,578,066.76, slightly up from RMB 428,401,115.84[15]. - Research and development expenses for Q1 2024 were CNY 6,664,605.96, slightly higher than CNY 6,559,933.54 in Q1 2023, showing an increase of about 1.60%[18]. - The company achieved an investment income of CNY 2,210,483.00 in Q1 2024, down from CNY 4,051,036.65 in Q1 2023, indicating a decline of about 45.49%[18]. Government Subsidies - The company received government subsidies amounting to CNY 688,457.24, a decrease of 28.14% compared to the previous year[9]. IPO Activity - The company is involved in the initial public offering of Zhejiang Fute Technology Co., Ltd., which received approval from the China Securities Regulatory Commission[12].

证券代码：002144 股票简称：宏达高科 公告编号：2024-015 2、会议召集人：公司董事会 3、本次股东大会会议召开符合《公司法》、《上市公司股东大会规则》 等有关法律法规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开时间 现场会议召开时间为：2024 年 5 月 28 日 14:00；通过深圳证券交易所 交易系统投票的具体时间为：2024 年 5 月 28 日 9:15—9:25，9:30—11:30 和 13:00—15:00；通过深圳证券交易所互联网投票系统投票的具体时间为： 2024 年 5 月 28 日上午 9:15 至下午 15:00 期间的任意时间。 5、会议召开方式 宏达高科控股股份有限公司 关于召开 2023 年年度股东大会的通知 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 根据宏达高科控股股份有限公司（以下简称"公司"）第七届董事会 第二十一次会议决议，公司决定于 2024 年 5 月 28 日召开公司 2023 年年 度股东大会（以下简称"本次股东大会"），现将本次股东大会有关事项通 知如下： 一、召开会议的基本情况 ...

Financial Performance - The company's operating revenue for 2023 was ¥535,183,326.15, a decrease of 7.63% compared to ¥579,374,030.06 in 2022[6]. - Net profit attributable to shareholders for 2023 was ¥82,253,031.59, representing a 3.22% increase from ¥79,684,521.83 in 2022[6]. - The net profit after deducting non-recurring gains and losses was ¥72,980,604.86, up 6.50% from ¥68,528,505.65 in 2022[6]. - The net cash flow from operating activities decreased by 8.58% to ¥75,228,177.61 from ¥82,286,518.13 in 2022[6]. - Basic and diluted earnings per share for 2023 were both ¥0.47, an increase of 4.44% from ¥0.45 in 2022[6]. - Total assets at the end of 2023 were ¥2,170,375,592.53, a slight increase of 0.23% from ¥2,165,349,466.00 at the end of 2022[6]. - Net assets attributable to shareholders increased by 2.54% to ¥1,995,956,420.04 from ¥1,946,575,091.25 at the end of 2022[6]. - The company reported a total of ¥9,272,426.73 in non-recurring gains for 2023, compared to ¥11,156,016.18 in 2022[26]. - The total operating revenue for 2023 was ¥535,183,326.15, a decrease of 7.63% compared to ¥579,374,030.06 in 2022[43]. - The revenue from fabric weaving was ¥381,831,004.62, accounting for 71.35% of total revenue, with a slight decrease of 1.55% year-on-year[43]. - The revenue from medical devices was ¥58,195,874.32, representing 10.87% of total revenue, with a decrease of 0.92% compared to the previous year[43]. - The company reported an investment income of ¥18,745,100 from joint ventures, including ¥1,584,890 from cash management of idle funds, an increase of ¥395,360 year-on-year[42]. - The total operating costs decreased by 14.52% to ¥357,548,791.31 from ¥418,300,936.47 in 2022[49]. - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2023, representing a year-over-year increase of 15%[110]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in Q3 2023, representing a 20% year-over-year growth[111]. Dividend Distribution - The company plans to distribute a cash dividend of 1.50 RMB per 10 shares to all shareholders, based on a total of 176,762,528 shares[6]. - The cash dividends represent 100% of the total profit distribution amount, with the remaining undistributed profit carried forward to the next year amounting to RMB 852,724,857.86[132]. - The company maintains a profit distribution policy that ensures at least 10% of the annual distributable profit is allocated for cash dividends when conditions are met[129]. - The company’s total distributable profit for the year is reported at RMB 74,498,758.46[131]. - The company has not proposed any stock dividends or capital reserve transfers during the current profit distribution plan[132]. - The company’s cash dividend distribution is in compliance with its articles of association and shareholder resolutions[131]. Business Transformation and Strategy - The company has undergone a significant business transformation since 2010, shifting its main operations from knitting to a dual focus on medical devices and fabric weaving[19]. - The company is actively pursuing high-value functional fabric markets and has seen a gradual increase in orders for high-end automotive interior fabrics[41]. - The company is focusing on the development of new energy vehicle interior fabrics to capture emerging market opportunities[41]. - The medical device subsidiary, Weierde, generated operating revenue of 69.48 million yuan, a decline of 1.16% year-on-year, but net profit rose by 10.23% to 18.72 million yuan[41]. - The company plans to expand its product line in ultrasound diagnostic equipment and explore niche markets such as veterinary ultrasound[41]. - The company aims to enhance its R&D and production capabilities in the fabric weaving sector, targeting new growth points in sports and leisure fabrics, and expanding into new fields such as rail transportation and civil aviation[83]. - The medical device subsidiary, Weirder, will increase R&D investment to improve product structure and market share, with plans for new production capacity to mitigate risks[85]. Market Conditions - The automotive market in China saw a 9.6% increase in passenger vehicle sales, reaching 26.124 million units in 2023[32]. - The market share of new energy vehicles exceeded 30% in 2023, with production and sales surpassing 9 million units[32]. - The textile industry saw a profit growth of 7.2% in 2023, with the overall revenue decline narrowing to 0.8% compared to the previous year[33]. - The Chinese medical equipment market is projected to reach 1.27 trillion yuan in 2023, reflecting a year-on-year growth of 10.4%[33]. Research and Development - Weierde holds over 120 patents related to ultrasound diagnosis and treatment, indicating a strong focus on R&D and innovation[38]. - R&D investment increased by 13.69% to ¥30,721,807.23 in 2023, representing 5.74% of operating revenue, up from 4.66% in 2022[63]. - The number of R&D personnel rose by 15.52% to 134 in 2023, with a proportion of 24.14% of total employees, an increase of 2.21% from 2022[63]. - The company completed several R&D projects aimed at enhancing ultrasound imaging technology and expanding its product line in the medical equipment sector[62]. - Research and development investments have increased by 40% this year, focusing on sustainable materials and advanced manufacturing techniques[110]. Governance and Management - The company has established a robust governance structure in compliance with regulatory requirements, ensuring effective decision-making and operational coordination[91]. - The company maintains complete independence from its controlling shareholder in terms of business, personnel, assets, and finance, ensuring autonomous operational capabilities[92]. - The board of directors consists of nine members, including three independent directors, complying with legal and regulatory requirements[93]. - The supervisory board is composed of three members, with one employee representative, ensuring effective supervision of major company matters[93]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, linking compensation to company performance[94]. - The company has a fully independent financial department with a separate accounting system and independent bank accounts, ensuring financial autonomy[97]. - The company has set up independent operational and management structures, with no overlap in personnel or offices with the controlling shareholder's enterprises[98]. - The company has maintained a stable management team with no resignations or dismissals reported during the current term[101]. Environmental Responsibility - The company reported a total environmental protection expenditure of 321,000 RMB for wastewater treatment, 192,000 RMB for air pollution control, and 43,700 RMB for solid waste disposal in 2023[149]. - The company achieved a 100% compliance rate for environmental monitoring data in 2023, meeting national requirements[148]. - The company processed 8,000 tons of wastewater daily, with 4,000 tons discharged and 4,000 tons reused[146]. - The company has implemented a comprehensive set of wastewater and air pollution control facilities, all operating normally and meeting discharge standards[146]. - The company completed carbon neutrality verification and received ISO 14064 greenhouse gas verification certificate, along with ISO 14067 carbon footprint verification certificates for two products[150]. Risks and Challenges - The main risks include market competition, particularly in the automotive fabric and medical device sectors, which are influenced by macroeconomic conditions[86]. - Raw material price fluctuations pose a risk to production costs, particularly for nylon and polyester used in fabric weaving[86]. - The company faces international market risks due to trade protectionism and potential currency fluctuations affecting exports[86]. - Financial risks include inventory depreciation and the potential for bad debts due to increased accounts receivable as the business expands[87]. - The company has a dual focus on medical devices and fabric weaving, which increases the complexity of management and decision-making[87]. Employee and Shareholder Engagement - The total number of employees at the end of the reporting period is 555, with 378 in the parent company and 177 in major subsidiaries[124]. - The professional composition includes 297 production personnel, 61 sales personnel, 134 technical personnel, 15 financial personnel, and 48 administrative personnel[125]. - The company has established a competitive and fair salary management policy to motivate employees and enhance their career development[126]. - The annual shareholders' meeting had a participation rate of 34.84% on May 25, 2023, reflecting shareholder engagement[99]. - The company has actively engaged with minority shareholders to consider their opinions and protect their rights[131].

天健审〔2024〕4361 号 宏达高科控股股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了宏达高科控股股份有限公司（以下简称宏达高科公司）2023 年 12 月 31 日的财务报告内部控制的有效性。 目 录 | 一、内部控制审计报告………………………………………………第 | 1—2 | | 页 | | --- | --- | --- | --- | | 二、附件………………………………………………………………第 | 3—7 | | 页 | | （一）本所营业执照复印件……………………………………… | 第 | 3 | 页 | | （二）本所执业证书复印件……………………………………… | 第 | 4 | 页 | | （三）本所从事证券服务业务备案完备证明材料……………… | 第 | 5 | 页 | | （四）本所签字注册会计师执业证书复印件…………………第 | 6—7 | | 页 | 内部控制审计报告 一、企业对内部控制的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》以及《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效 ...

宏达高科控股股份有限公司 2023 年度财务决算报告 一、财务报表审计意见 天健会计师事务所（特殊普通合伙）对公司 2023 年财务报表进行审计，并于 2024 年 4 月 24 日出具了标准无保留意见的审计报告（天健审〔2024〕4356 号），认为公司财务报表在所 有重大方面按照企业会计准则的规定编制，公允反映了公司 2023 年 12 月 31 日的合并及母公 司财务状况，以及 2023 年度的合并及母公司经营成果和现金流量。 二、主要财务数据与财务指标 报告期内公司共实现营业收入 53,518.33 万元，较上年下降 7.63%，本期归属于上市公 司股东的净利润为 8,225.30 万元，较上年上升 3.22%。本报告期，公司对海宁宏达股权投资 管理有限公司的长期股权投资计提资产减值准备 1,951.02 万元，较去年同期增加 607.01 万 元。公司归属于上市公司股东的扣除非经常性损益的净利润为 7,298.04 万元，较去年同期上 升 6.50%。公司整体财务状况良好，持续多年实现盈利，目前资产负债率较低。报告期期末 归属于上市公司股东的所有者权益为 199,595.64 万元，同比增加 2.5 ...

宏达高科控股股份有限公司 独立董事关于 2023 年度独立性情况的自查报告 本人高琪，于 2020 年 1 月起担任宏达高科控股股份有限公司（以下简称"上市公司 "）独立董事，在 2023 年度任职时间为 2023 年 1 月 1 日至 2023 年 12 月 31 日。 | 序号 | 事项 | | 自查结果 | | | --- | --- | --- | --- | --- | | 1 | 在上市公司或者其附属企业任职的人员及其配偶、父母、子女、主 | 是 | 否 |  | | | 要社会关系； | | | | | 2 | 直接或者间接持有上市公司已发行股份百分之一以上或者是上市 | 是 | 否 |  | | | 公司前十名股东中的自然人股东及其配偶、父母、子女； | | | | | 3 | 在直接或者间接持有上市公司已发行股份百分之五以上的股东或 | 是 | 否 |  | | | 者在上市公司前五名股东任职的人员及其配偶、父母、子女； | | | | | 4 | 在上市公司控股股东、实际控制人的附属企业任职的人员及其配偶 | 是 | 否 |  | | | 、父母、子女； | | | | | ...

宏达高科控股股份有限公司 Hongda High-Tech Holding Co.,Ltd. （002144） 2023 年度社会责任报告 2024 年 4 月 1 报告概述 一、报告简介 随着全球经济的深度融合和可持续发展理念的深入人心，企业社会责任已 成为衡量企业综合竞争力的重要指标。《公司2023年度社会责任报告》回顾了 宏达高科控股股份有限公司（以下简称"公司"）2023年度在实现自身稳健发展 的同时，始终坚守社会责任，积极维护股东、员工、供应商、客户等利益相关 方的权益，以实际行动推动社会的和谐与进步。 二、编制依据 本报告是根据《深圳证券交易所上市公司自律监管指引第1号——主板上市 公司规范运作》、《上市公司自律监管指引第5 号——信息披露事务管理》、 《主板信息披露业务备忘录第1号：定期报告披露相关事宜》的要求，参考《中 国企业社会责任报告编写指南》、《社会责任指南》的内容和格式，并结合公 司的实际情况编写而成。 三、时间范围 本报告期间为2023年1月1日至2023年12月31日，部分内容适度向前延伸。 四、发布周期 本报告为年度报告，每年与宏达高科控股股份有限公司年度报告同时发 布。 五、报 ...

2024 宏达高科控股股份有限公司（以下简称"公司"）第七届董事会独立董事 专门会议2024年第一次会议于2024年4月24日以现场方式召开。本次会议独立董 事应参加3名，实际参加3名。经全体独立董事同意，共同推举平衡先生作为公司 第七届董事会独立董事专门会议召集人并主持本次会议。本次独立董事专门会 议的召开符合《公司法》、《上市公司独立董事管理办法》和《公司章程》的有 关规定。本次会议形成以下审核意见： 一、关于《2023年度利润分配预案》的审核意见 表决结果： 3票同意、 0票弃权、 0票反对。 发表审核意见如下：2023年度利润分配预案是公司考虑到实际经营情况及 后续发展资金需求作出的决定，符合公司章程规定，不存在损害股东尤其是中小 股东利益的情况。因此，我们一致同意公司2023年度利润分配预案。 二、关于《2023年度内部控制自我评价报告》的审核意见 表决结果： 3票同意、 0票弃权、 0票反对。 根据《企业内部控制基本规范》等相关规定的要求，我们认真阅读报告 内容，并与公司管理层和有关管理部门交流，查阅公司的管理制度，基于独立判 断，发表审核意见如下： 1.公司内部控制制度符合国家有关法规和证券监管 ...